Latest Asx Company Filings News

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.

Australian Gold and Copper Ltd has significantly expanded its South Cobar exploration footprint through key acquisitions and reported strong high-grade drilling results at its Achilles deposit, underpinning its growth strategy.

Visionflex Group reported a $999,000 cash outflow for Q1 2025 but bolstered its liquidity with $1.9 million in financing, including plans to convert $3 million of convertible notes into equity pending shareholder approval.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.

Aspermont Limited reports a milestone $11.2 million annual recurring revenue with its new Mining-IQ platform gaining traction through a landmark Rio Tinto contract. The company also strengthens its balance sheet with a $2.8 million capital raise, setting the stage for accelerated growth.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 50 active trials worldwide and anticipates its first significant sales this quarter, supported by fresh funding and expanding market interest.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

CAR Group Limited has reported robust FY25 financial results with strong revenue and profit growth, underpinned by strategic investments in AI and digital marketplaces. The company projects continued momentum into FY26, aiming to deepen market leadership across global regions.

Endeavour Group’s first quarter results reveal a strong Hotels segment growth of 4.4%, alongside a retail sales recovery that returned to positive territory in September. Online sales surged by 20.9%, highlighting shifting consumer habits.